Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
about
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDSProvider training and experience for people living with HIV/AIDSA combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDSSystematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy.Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy eraA tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessationPharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavirDPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variantsACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replicationDevelopment and validation of a composite programmatic assessment tool for HIV therapySignificantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram dataDrug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxisIn vitro and ex vivo evaluations on transdermal delivery of the HIV inhibitor IQP-0410Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010)Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitorsThe HIV-1 Nef protein as a target for antiretroviral therapy.Ongoing trials in HIV protease inhibitors.Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs.Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms.Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study.Development of topical microbicides to prevent the sexual transmission of HIVLack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011.Factors related to loss of child custody in HIV+ women in drug abuse recovery.Examining family networks of HIV+ women in drug recovery: challenges and opportunitiesEvidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1Treatment Options for HIV-Associated Tuberculosis.Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial dataMedication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuseModulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.HIV-1 protease inhibitors.Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma.Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir
P2860
Q24200188-4A106BE1-7169-4A6F-98D2-D76BAA070EE8Q24236582-1D7E2C06-5656-4DF3-AE64-DC6EF79577D8Q24239831-4482CE1E-39ED-497F-BCD8-CAE6420C5718Q24514773-EAB04968-0038-46ED-88E7-6548CE504682Q24632654-114D920F-530A-4070-8400-BA8271244852Q27319650-920CB15E-00A0-43F9-B192-CE889CD79E85Q28345258-8F4AAB99-8148-4F5C-84E4-A7ED51764B04Q28361560-6F5B0836-C2D1-4D76-AA36-3A8287C4F98FQ28362780-46A55E0A-8D29-484D-837C-16471BCFDA2AQ28364133-8B264F2F-33FC-4BD1-B2A2-42CD965FA60FQ28485260-FB227E4C-6FE9-4A9F-996A-D1CE9DE01D3CQ28486299-719806CC-614B-450A-B73D-DB3B7DCA982DQ28486428-3351D2D7-3F25-470B-AAC6-CAF5ECE0AAA1Q28533587-D991742C-06C7-4A93-AC4B-170388062D3FQ28541096-BED1140C-2EB3-4116-9A86-B8C1A7DB4BC2Q28545757-87308C51-4565-4886-900B-FA28FEA11ACEQ30160188-A5C1DEAA-2818-40B0-A2DF-31A3A8BF11B6Q30327423-888DC6CC-2CBF-4B91-A650-9A4E630DE501Q30621065-7C97D979-74BF-450C-BA10-14A8531F7E11Q30762478-DCD637F5-EA5D-4EB2-989F-DC09982F37BAQ31430709-3CFA5127-C7D4-45A1-87AE-A10687C2E1DDQ33313949-8657FE62-D00E-49ED-9419-919BE846625BQ33341768-C1CB8C5C-3E70-457D-AB39-22FC8BF476EAQ33598342-48EF2E50-749D-434F-B438-0D738D03AA7BQ33625073-84C10FD3-DAEC-4EF3-BEB4-1BD20472AB66Q33676340-EE809781-1693-44BA-B5D7-774FE0AB57F7Q33713411-652D4750-417A-4C9B-B045-CF07E5D24C7BQ33725888-4E93C265-2C24-4C7E-9B25-F1E2AE422454Q33753330-68C4568C-7DD0-400D-83A9-034069CEE071Q33811164-78F56D75-029F-4487-BDED-64E2747A2662Q33813097-99CAFDE4-DFC6-4400-9E21-D56200751C74Q33891656-EE8B55AF-026D-4A84-8298-A500D7BCD2AEQ33917628-79100CC5-5E07-403A-9CCA-0BC53858BC98Q33945359-A892DD6E-6DE1-4CDE-B781-1BDBD7DAA6B0Q33946920-35BC26FB-FAD4-4752-8354-4377E32A88B0Q33968714-5E62CE5F-3E7A-4E3D-982E-D0770F405553Q33971117-9ADE4D3F-C9F7-4193-9BED-3FE2FF243084Q33979107-9F84ED26-2ECE-4395-8217-87F866AE5D7DQ33983571-A180CBF8-9669-4880-A909-ABEDD2B9FCCFQ33983801-D4043A50-0FA9-413C-B612-328649FBDDA0
P2860
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antiretroviral therapy in adul ...... tional AIDS Society-USA Panel.
@ast
Antiretroviral therapy in adul ...... tional AIDS Society-USA Panel.
@en
type
label
Antiretroviral therapy in adul ...... tional AIDS Society-USA Panel.
@ast
Antiretroviral therapy in adul ...... tional AIDS Society-USA Panel.
@en
prefLabel
Antiretroviral therapy in adul ...... tional AIDS Society-USA Panel.
@ast
Antiretroviral therapy in adul ...... tional AIDS Society-USA Panel.
@en
P2093
P356
P1476
Antiretroviral therapy in adul ...... tional AIDS Society-USA Panel.
@en
P2093
B G Gazzard
C C Carpenter
D A Cooper
D A Katzenstein
D D Richman
D M Jacobsen
J M Gatell
J S Montaner
M A Fischl
M A Thompson
P304
P356
10.1001/JAMA.283.3.381
P407
P577
2000-01-01T00:00:00Z